Newspaper Advertisement
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
JB Chemicals & Pharmaceuticals published its AGM notice and audited consolidated financial results for the quarter and year ended March 31, 2026. For FY 2025-26, consolidated revenue from operations stood at Rs 9,787.2 crore, a significant jump from Rs 3,345.6 crore in the previous year. However, net profit after tax declined to Rs 40.8 crore from Rs 60.3 crore in FY25, with basic EPS dropping to Rs 2.8 from Rs 7.9. Q4 FY26 revenue was Rs 2,789.9 crore with net profit of Rs 82.5 crore. The company recognised a statutory impact of Rs 32 crore (gratuity and compensated absences) under new Labour Codes as an exceptional item. The Board recommended a dividend of Rs 5 per share (250% on face value of Rs 2). The 75th AGM is scheduled for June 17, 2026 via video conferencing.
Revenue surged significantly year-on-year, likely due to acquisitions or organic growth, but profitability declined sharply with EPS falling to Rs 2.8 from Rs 7.9, which could concern investors. The dividend declaration provides some positive signal for shareholder returns despite lower earnings.